Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
269,417people with type 2 diabetes, in this paper
Already taking metformin, or nottheir own situation, not assigned
on metformin
not on metformin users
Metformin went with lower overall survival−31%
Metformin went with lower cancer-specific survival−25%
No clear link with disease-free survival−62%
correlation, not a testthe abstract, start to end
… HRs for OS in metformin users were 0.69 (95% CI, 0.61-0.77).
… by the trim-and-fill method (adjusted HR 0.77, 95% CI, 0.67-0.87) confirmed …
… associated with patient CS (HR 0.75, 95% CI, 0.59-0.94), but not DFS (HR 0.38, 95% CI, 0.13-1.17).
← favours treatmentfavours comparator →
could be chanceOverall survival (OS)metformin vs non-metformin users, in diabetic CRC patients
HR 0.690.61–0.77
Overall survival (OS)metformin vs non-metformin users
HR 0.770.67–0.87
Cancer-specific survival (CS)metformin vs non-metformin users
HR 0.750.59–0.94
Disease-free survival (DFS)metformin vs non-metformin users
HR 0.380.13–1.17
MetforminAll-cause mortality
1 / 4